ABSTRACT
Protein C (PC) is a vitamin K-dependent product of the liver, present in the blood similar to inactivated zymogene pro-enzyme and has antithrombotic, anti-inflammatory, and pro-fibrinolytic properties. During severe sepsis there is a reduction in PC concentration. PC deficiency leads to increased activation of the coagulation system, resulting in thrombin generation and, eventually, intravascular clot formation with thrombosis. (1) Numerous studies have demonstrated that decreased circulating levels of PC in septic patients are associated with increased morbidity and mortality. (2-7) The inflammatory and pro-coagulant host responses to infection are closely related. Inflammatory cytokines can activate coagulation, inhibit fibrinolyis and stimulate multiple inflammatory pathways, resulting in multi-organ dysfunction and death. PC is converted to activated PC (APC) by thrombin coupled to thrombomodulin in a selective way during the coagulation cascade by inhibiting platelet activation and fibrin production, and is an important modulator of the coagulation and inflammation associated with severe sepsis. (8) PC is presently utilized as therapy for patients with congenital deficiency of PC, and for purpura fulminans treatment. (9) (10) (11) In children and in patients with contraindications to the activated form of PC, such as those at high risk of bleeding, PCc administration seems to be a useful alternative to APC: we'll review the published evidence on this topic. Even if Recombinant Human Activated Protein C (rhAPC, Xigris, Lilly) reduces all cause mortality in adult patients with sepsis-induced organ dysfunction with clinical assessment of high risk of death (typically APACHE II > 25 or multiple organ failure), (12) its use is associated with an increased risk of serious bleeding: 2% vs 3.5% (PROWESS study), (13) 2.2% vs 3.9% (ADDRESS study), (14) 6.5% (ENHANCE), (15) with registry studies of rhAPC (16, 17) (25) increased their published experience describing the use of PC as repeatable boluses of 100 u/kg four-a-day, associated with anti thrombin III (AT III) supply to reach normal values in 12 patients affected by purpura fulminans, one manifestation of disseminated or overt disseminated intravascular coagulation (DIC), characterized by thrombocytopenia, petechiae, ecchymoses associated with thrombosis of small vessels, resulting in tissue hypoperfusion that leads to peripheral gangrenes and acute renal failure. Nine of 12 patients were in septic shock and others in severe sepsis; median APACHE II score was 16. Median PC activity was 26%, median platelet count 27000. Etiology of infection was N. meningitidis in 4 patients, S. pneumoniae in 2, C. canimorsus in 2 and 1 S. aureus, in 2 the etiology was unknown. Authors reported withdrawal of acrocyanosis, restriction of ischemic regions and improvement of peripheral temperature within the first few days of treatment, with concurrent improvement of hemodynamic disturbance. Laboratory tests showed improvement of DIC status. Two patients required amputations. Twenty-eight day mortality was 33% (4 of 12) and hospital mortality 42% (5 of 12). They didn't observe any drug related adverse events. In a post hoc analysis, authors showed that the recovery of the platelet count was retarded in the non-survivor group. The largest experience so far has been reported by Baratto e al. (19) who described the efficacy and safety of PCc to restore physiological values in 20 adult septic patients having clinical contraindications to treatment with rhAPC such as platelets <30.000 (9 patients), neurological pathologies (4 patients), high bleeding risk (3 patients), pending major surgical interventions (2 patients), and anticoagulant drug therapy (2 patients). They found a significant increase of platelets PT, AT III, and a significant decrease of D-Dimer, aPTT, DIC score and lactate. They administered PCc with the aim to obtain 100% of the plasma PC activity using the formula: IU of PCc= (100 -PC plasma level) x body weight (Kg). Continuous infusion lasted 72 hours and started at 3 IU/kg/h, adjusted it to 
Conclusions
The published literature on the use of protein C concentrates in adult septic patients is encouraging (normalization of coagulative parameters, no bleeding complications and low 30 day mortality) even if limited to less than 70 patients, including those presented in this paper. While rhAPC evidenced an increased risk of bleeding complications in randomized controlled trials versus placebo, and registry studies report even higher bleeding rates than those present in the randomized controlled trials, (16) (17) no bleeding complication has ever been reported following infusion of PCc in adults or children. Nonetheless, in order to recommend the use of PCc in the management of severe sepsis and septic shock it would be necessary to confirm these encouraging findings with a randomized multicenter controlled trial.
